Yu dɔn yɛri bɔt Kronik Limfosaytik Lukimiya (CLL)? Lɛ wi tɔk bɔt am ditayli!

Sɔntɛnde, yu kin jɔs fil se yu taya bad bad wan? Ɔ bɔku tɛm yu kin gɛt fiva? Yu gɛt smɔl smɔl smɔl smɔl smɔl smɔl smɔl smɔl smɔl smɔl smɔl smɔl smɔl smɔl smɔl smɔl smɔl smɔl smɔl smɔl smɔl smɔl smɔl smɔl smɔl smɔl smɔl smɔl smɔl smɔl smɔl smɔl smɔl smɔl smɔl smɔl smɔl smɔl smɔl smɔl smɔl smɔl smɔl smɔl smɔl smɔl smɔl smɔl smɔl smɔl smɔl smɔl smɔl smɔl smɔl smɔl smɔl smɔl smɔl smɔl smɔl smɔl smɔl smɔl smɔl smɔl smɔl smɔl smɔl smɔl smɔl smɔl smɔl smɔl smɔl smɔl smɔl smɔl smɔl smɔl smɔl smɔl smɔl smɔl smɔl smɔl smɔl smɔl smɔl smɔl smɔl smɔl smɔl smɔl smɔl. Dɛn tin ya kin bi sayn dɛm fɔ Chronic Lymphocytic Leukemia, ɔ CLL fɔ shɔt tɛm. Bɔt nɔr wɔri, bikɔs fɔ gɛt ɔl dɛn sayn ya nɔr min se yu gɛt dis sik. Bɔt i rili impɔtant fɔ no bɔt tin dɛn lɛk dis. So mek wi tok abaut CLL fo simpul we tide, okay?

Wetin na kronik limfosaytik lukimiya (CLL)? Fɔ tɔk am simpul wan...

Chronic lymphocytic leukemia (CLL) na wan kayn blɔd kansa . Na di kayn lukimiya we kin kam pan big pipul dɛn. Blɔd sɛl dɛn de kɔmɔt na di bon mɛro. dis kכndyushכn kin apin we di limfosayt dεm, we na wan kayn hεlty wayt blכd sεl na di bon mכro, nכ de nכmal, we min se dεn de chenj εn bi kεnsar. Dɛn kansa sɛl dɛn ya kin bɔku we dɛn nɔ kin ebul fɔ kɔntrol dɛnsɛf, ɛn dɛn kin krawd di wɛlbɔdi blɔd sɛl dɛn ɛn di pletlɛt dɛn, we kin ɛp fɔ mek di blɔd klɔt.

CLL kin apun bɔrku tɛm pan pipul dɛm wae dɔn pas 65. Bɔt sɔmtɛm e kin apun to pipul dɛm wae yɔŋ lɛk 30. Wetin pas dat, sɔm pipul dɛm kin gɛt CLL wae nɔr gɛt ɛni sayn . Bɔrku pipul dɛn kin no bɔt dis sik wae dɛn kin du blɔd tɛst fɔ ɔda sik ɔr wae dɛn kin du mɛrɛsin ɛvri ia.

Naw, no mɛrɛsin nɔ de fɔ CLL. Bɔt dat nɔto sɔntin we de mek wi wɔri. Insay di las tɛn ia, dɔktɔ dɛn dɔn mek nyu tritmɛnt dɛn we go ebul fɔ kɔntrol CLL ɛn put am na remission . Dɛn tritmɛnt ya dɔn mek pipul dɛm wae gɛt CLL liv lɔng pasmak.

Wetin na di men kayn CLL?

Tu men kayn wayt blɔd sɛl dɛn de na wi bɔdi, we dɛn kɔl limfosayt. CLL kin divɛlɔp insay wan pan dɛn tu kayn ya nɔmɔ.

• B-limfosayt dεm (B-sεl dεm): Dis na di sεl dεm we de mek antibodi dεm, we na wan kayn protin we de no εn fכ fɛt di bad bad jεm dεm, baktri dεm, vayrus dεm, εn ivin kεnsar sεl dεm.
• T-limfosayt dεm (T-sεl dεm): dεn ya de kכntro di we aw wi bכdi in imyun sistεm de ansa. Dɛn kin fɛn ɛn pwɛl di sɛl dɛn we nɔrmal, lɛk di kansa sɛl dɛn bak ɛn pwɛl dɛn dairekt wan.

Di kayn CLL we kɔmɔn pas ɔl na B-sɛl CLL . wan kכndyushכn de we de fכm we de afekt di T-sεl dεm, we dεn kכ l T-sεl prolymphocytic leukemia (PLL). Bɔt pipul dɛn we gɛt PLL kin gɛt di sik kwik kwik wan pas pipul dɛn we gɛt B- sɛl CLL.

Aw kɔmɔn tin we dɛn kɔl dis kɔndishɔn CLL?

Infakt, kronik lymphocytic leukemia (CLL) na wan pan di kayn lukimiya we kin kam pan big pipul. Insay Amɛrika, dis sik kin ambɔg lɛk 5 pan ɔl 100,000 pipul dɛn. Di American Cancer Society tɔk se na lɛk 18,700 nyu pipul dɛn go gɛt CLL insay 2023 nɔmɔ. Fɔ put dis na di rayt we, dɛn tink se dɛn go ripɔt pas 238,000 nyu kes dɛm we gɛt lɔng kansa (wan pan di kansa dɛm we kin bɔku pas ɔl) insay 2023. So, pan ɔl we i nɔ kin tan lɛk se CLL nɔ kɔmɔn so, na wan pan di kayn lukimiya we kin bɔku.

Wetin na di sayn dɛm fɔ CLL?

As wi bin dɔn tɔk, sɔm pipul dɛn kin gɛt CLL we nɔ gɛt ɛni sayn . E kin tek sɔm mɔnt ɔr ivin sɔm ia fɔ mek di sayn dɛm fɔ sho. De sayn dɛm wae kin kam pan pɔrsin na:

• Taya: CLL kin afɛkt yu rɛd blɔd sɛl dɛn, ɛn mek yu nɔ gɛt bɛtɛ blɔd. Taya na wan sayn we kin sho se pɔsin nɔ gɛt bɛtɛ blɔd.
• Fiva: Fiva na sayn fɔ se yu gɛt di sik. Bikɔs CLL kin afɛkt di wayt blɔd sɛl dɛn we gɛt wɛlbɔdi, yu kin gɛt infɛkshɔn mɔ.
• di limf no dεm we swεl na di nεk, di armpit, di groin, כ di bεlε.
• Nayt swet dɛn.
• We yu de lɔs yu wet we yu nɔ ɛksplen.
• Pen ɔ fil fɔ ful ɔnda yu rib: CLL kin afɛkt yu liva ɔ splin. We kansa sɛl dɛn gɛda na dɛn ɔgan dɛn ya, dɛn kin swel.

Wetin mek CLL de divɛlɔp? Wetin na di tin dɛn we kin mek pɔsin gɛt dis sik?

Kronik limfosaytik lukimiya (CLL) kin kam we sɔm chenj dɛn, ɔ chenj dɛn kin apin na wi kromozom ɛn jin dɛn we wi de liv. Bɔt di wan dɛn we de stɔdi bɔt mɛrɛsin stil nɔ shɔ wetin de mek dɛn chenj ya. Bɔt dɛn dɔn no bɔku tin dɛn we kin mek i gɛt prɔblɛm:

• Famili istri: Risach dɔn sho se if wan pan yu fambul dɛn we de nia yu, dat na yu mama, papa, brɔda ɛn sista, ɔ pikin dɛn gɛt CLL, yu risk fɔ gɛt CLL kin go ɔp tu to 4 tɛm.
• Ej: Na avrej, di sik pipul dɛn kin ol lɛk 71 ia we dɛn no se dɛn gɛt CLL.
• Sɛks: Man dɛn kin gɛt CLL mɔ.
• Fɔ gɛt Ejen Ɔrɛnj: Risach dɔn sho se wan link de bitwin Ejen Ɔrɛnj, we na wan kemikal we dɛn bin de yuz insay di Vietnam Wɔ, ɛn CLL.
• Monoklonal B-sεl limfosaytכsis:Insay dis kɔndishɔn, yu gɛt mɔ wan kayn B-sɛl na yu blɔd pas aw yu kin gɛt. If yu gɛt dis sik, yu gɛt smɔl risk fɔ gɛt CLL.

Wetin na di prɔblɛm dɛn we kin apin we pɔsin gɛt CLL?

CLL kin afɛkt yu rɛd blɔd sɛl dɛn, wayt blɔd sɛl dɛn, ɛn yu pletlɛt dɛn. Tink bɔt am, di rɛd blɔd sɛl dɛn kin kɛr ɔksijɛn go ɔlsay na di bɔdi. Wait blɔd sɛl dɛn de protɛkt wi frɔm sik. Plɛtlɛt dɛn kin ɛp fɔ mek blɔd klɔt. So, we yu lɔs dɛn wɛlbɔdi blɔd sɛl ɛn pletlɛt ya, yu kin gɛt prɔblɛm dɛn lɛk:

• Limfoma: Bitwin 2% ɛn 10% pan di pipul dɛm we gɛt CLL kin gɛt wan kayn kansa we dɛn kɔl limfoma.
• Kansa na yu skin, kansa na yu lɔng, ɔ kansa na yu kɔlon: CLL de mek yu imyun sistɛm wik, ɛn dis de mek i nɔ ebul fɔ protɛkt yu frɔm di wan dɛn we de kam insay yu, ivin di kansa sɛl dɛn. Dis kin mek yu gɛt ɔda kayn kansa.
• Anemia: Anemia kin kam we di rεd bכdi sεl dεm nכ de fכ kכri כksijεn כlsay na di bכdi.
• Trombocytopenia: CLL kin afɛkt yu pletlet saplai. Dis kin mek yu blɔd kɔmɔt.
• Yu kin gɛt infɛkshɔn ɔltɛm: If yu nɔ gɛt bɛtɛ wayt blɔd sɛl dɛn we gɛt wɛlbɔdi, yu go gɛt baktri, fɛns, ɔ vayral infɛkshɔn.
• Ɔtoimyun sik dɛm: Sɔm pipul dɛm wae gɛt CLL kin gɛt tin dɛm lɛk ɔtoimyun ɛmolaytik anemia.

Aw dɛn kin no se pɔsin gɛt CLL?

We yu go to dɔktɔ, i go aks yu bɔt di sayn dɛn we yu gɛt. Dɔn, dɛn go du ɛgzam fɔ dɛn bɔdi ɛn dɛn kin ɔda sɔm tɛst dɛn, lɛk:

• Kɔmplit blɔd kɔnt (CBC) ɛn difrɛns: Dis tɛst de mɛzhɔ di nɔmba fɔ di rɛd blɔd sɛl dɛn, wayt blɔd sɛl dɛn, ɛn di pletlɛt dɛn we de na yu blɔd. I de chɛk bak ɔmɔs ɛmoglobin (di prɔtin we de kɛr ɔksijɛn) de na yu rɛd blɔd sɛl dɛn.
• Peripheral blood smear: Wan mɛdikal lɛbɔraytri tɛknishian de chɛk yu blɔd sɛl dɛn ɔnda maykroskɔp fɔ chɛk if yu gɛt kansa sɛl dɛn.
• Flɔ saytometri: Dis lab tɛst kin gi mɔ infɔmeshɔn bɔt yu blɔd sɛl dɛn. Insay CLL, dɛn kin yuz am fɔ no if yu wayt blɔd sɛl dɛn gɛt CLL sɛl dɛn.
• Jɛnɛtik tɛst dɛn:Dɔktɔ dɛn kin yuz tɛst dɛn lɛk fluorescent in situ hybridization (FISH) ɛn immunoglobulin heavy chain (IGHV) fɔ chɛk yu kromozom ɛn jin dɛn. We dɔktɔ dɛn ɔndastand wetin chenj dɔn apin na dɛn kromozom ɛn jin ya, dat kin ɛp di dɔktɔ dɛn fɔ disayd aw fɔ trit CLL.

Stej dɛn fɔ CLL

Dɔktɔ dɛn kin disayd di stej we di kansa gɛt fɔ plan di tritmɛnt ɛn fɔ tɔk wetin go apin to am. Tu men we dɛn de we dɛn kin yuz fɔ stej CLL: di Rai stej sistɛm ɛn di Binet stej sistɛm .

Sɔntɛnde, we yu rid dɛn stej ya wit nɔmba ɛn lɛta, yu kin fred smɔl ɛn nɔ kin fil fayn. Yu kin ivin tink se, "Na so dɛn kin tɔk bɔt mi sik na fɔmula?" Dɔktɔ dɛn ɔndastand dat. If yu nɔr klia bɔt wetin dɛn de tɔk, ɔr if i de tranga fɔ yu, duya aks yu dɔktɔ fɔ ɛksplen aw dis stej sistɛm de aplay to yu kɔndishɔn.

Rai stej sistem

Dis we ya de klas CLL akɔdin to di chans fɔ mek i wɔs ɛn if dɛn go nid tritmɛnt:

• lכw risk (dεn bin kכl am Rai stej 0): Yu gεt limfosayt (we de inkrεs pan di nכmba fכ di limfosayt dεm), εn abnכmal wayt blכd sεl dεm de na di bכdi εn/כ bon mכro.
• intamεdiεt risk (dεn bin kכl am Rai stej I כ stej II): Yu gεt limfosaytosis, limf no dεm we swεla, εn splin εn/כ liva we big.
• High risk (dεn bin kכl am Rai Stej III): Yu gεt anemia כ trombocytopenia (low pletlet count).

Binet stej sistem

Dis we ya de bays pan yu blɔd sɛl ɛn pletlɛt kɔnt, ɛn bak di nɔmba fɔ di say dɛn we gɛt swɛlin limf no dɛn na yu bɔdi:

• Stej A: Yu nɔ gɛt anemia (lɔ rɛd blɔd sɛl kɔnt) ɔ low pletlɛt kɔnt. Bɔt yu gɛt limf no dɛn we dɔn swel na at le tu ples dɛn na yu bɔdi. Fɔ ɛgzampul, yu kin gɛt limf no dɛn we dɔn swel na yu nɛk ɛn yu groin.
• Stej B: di limf no dεm we swel de na tri ples na di bכdi, כ di liva כ di splin swεla. Bɔt, no anemia nɔ de, ɛn di pletlɛt lɛvɛl nɔmal.
• Stej C: Yu gɛt anemia ɛn yu gɛt swɛlin limf no dɛm na tri ɔ mɔ ples na yu bɔdi.

Aw dɛn kin trit CLL?

Dɛn kin no di tritmɛnt opshɔn dɛm bay yu simptom dɛm ɛn di tɛst rizɔlt dɛm. Fɔ ɛgzampul, if yu gɛt CLL we yu dɔn bigin, yu dɔktɔ kin se yu fɔ "watchful waiting/active surveillance."Yu kin go wit di we aw dɛn kɔl "monitoring." Dis kin min fɔ tek tɛm wach yu jenɛral wɛlbɔdi, di sayn dɛm, ɛn di tɛst rizɔlt dɛm we yu nɔ bigin fɔ tek tritmɛnt.

Di tin dɛn we kin kɔmɔt frɔm di jenɛtik tɛst kin afɛkt bak di tin dɛn we dɛn kin disayd fɔ du fɔ di tritmɛnt. Fɔ ɛgzampul, sɔm chenj dɛn na yu jɛnɛtiks kin min se yu sik kin wɔs kwik kwik wan, ɔr di standad CLL tritmɛnt dɛn nɔ kin wok fayn lɛk aw yu bin de tink.

Di tritmɛnt dɛn we dɛn kin yuz mɔ fɔ CLL na targeted therapy ɛn kemotherapy . Sɔntɛnde, dɛn kin yuz redyushɔn tɛrapi fɔ ridyus di sayn dɛm fɔ CLL. Ɛni wan pan dɛn tritmɛnt ya kin mek pɔsin gɛt difrɛn sayd ɛfɛkt dɛn. Yu dɔktɔ go ɛksplen klia wan bɔt di bɛnifit dɛn, di bad tin dɛn we kin apin to yu, ɛn di prɔblɛm dɛn we kin apin fɔ lɔng tɛm we di tritmɛnt we yu de gɛt kin gɛt.

Targeted therapy

Dis tritmɛnt de wok bay we i de tɔch di kansa sɛl dɛn. Insay kronik lymphocytic leukemia, dis tritmɛnt de wok bay we i de stɔp di wayt blɔd sɛl dɛn we gɛt kansa fɔ gro. Sɔm tritmɛnt dɛn we dɛn kin yuz fɔ mɛn kansa kin kil di kansa sɛl dɛn we nɔ kin ambɔg di sɛl dɛn we gɛt wɛlbɔdi. Sɔm pan di mɛrɛsin dɛn we dɛn kin yuz fɔ dis na:

• Bruton in tyrosine kinase (BTK) inhibitor therapy: Dis tritmεnt de blכk wan εnzym we de εp di B-sεl dεm fכ mek mכr wayt bכdi sεl dεm. Ɛgzampul dɛn: ibrutinib (Imbruvica®) , akalabrutinib (Calquence®) , ɛn zanubrutinib (Brukinsa ®) .
• BCL2 inhibitor therapy: di drog venetoclax (Venclexta®) de blok wan protin we dεn kכl BCL2 we de insay lukimiya sεl dεm, inklud CLL sεl dεm. Dis tritmɛnt kin kil di lukimiya sɛl dɛn ɔ mek dɛn fil fayn to ɔda mɛrɛsin dɛn we de mek dɛn nɔ gɛt kansa.
• Monoclonal antibody therapy: Dis na wan kayn imyunotɛrapi. monoklonal antibodi dεm na wan kayn antibodi we dεn mek na labכtכri. Dɛn kin stɔp di kansa sɛl dɛn we de gro ɔ kil di kansa sɛl dɛn. Ɛgzampul dɛn: rituximab (Rituxan®) ɛn obinutuzumab (Gazyva®) .

Kimotɛrapi

Yu dɔktɔ kin yuz kemotɛrapi as di men tritmɛnt fɔ kronik lymphocytic leukemia. Sɔm pan di kemotɛrapi mɛrɛsin dɛn we dɛn kin yuz fɔ CLL na:

• Fludarabin (Fludarabin - Fludara®) .
• Klorambusil (Klorambusil - Lukeran®) .
• Sayklɔfosfamid (Saytoksan®) .
• Bɛndamustin (Bɛndamustin - Treanda®) .

Imyunotɛrapi

Dis tritmɛnt we de wok bay we i de mek yu imyun sistɛm kam bak ɔ mek yu gɛt mɔ trɛnk, ɛn i de ɛp fɔ pwɛl di kansa sɛl dɛn ɔ fɔ mek dɛn nɔ gro sloslo.

Fɔ CLL we nɔ ansa to kemotɛrapi, we dɔn kam bak (rikɔrɛnt) CLL, ɔ we de wɔs, dɔktɔ dɛn kin yuz di imyunotɛrapi drɔg lenalidomide (Revlimid®) .

Medikal risach pipul dεm de stכdi bak chimeric antigen receptor (CAR-T) tεrapi fכ CLL pasεnshכn dεm we nכ de rεspכnd to standad tritmεnt dεm.

Aw lɔŋ yu kin liv wit CLL?

Kronik limfosaytik lukimiya (CLL) kin go bifo smɔl smɔl. Yu kin liv wit CLL fɔ lɔng tɛm bifo yu gɛt di sayn dɛm. Wans di sayn dɛn dɔn sho, dɔktɔ dɛn kin gɛt tritmɛnt dɛn we rili fayn we kin put CLL insay di rɛmishɔn . Dis rεmishכn frכm CLL kin te fכ sכm ia bifo di sik kam bak. Bɔt yu dɔktɔ kin tɛl yu ɔda tritmɛnt dɛn we kin put CLL insay rɛmishɔn bak. CLL nɔr kin wɛl ɔl, bɔt pipul dɛm wae gɛt dis sik kin liv lɔng, ful layf.

Di Nashɔnal Kansa Instityut tɔk se 87.9% pan di wan dɛn we gɛt CLL de alayv fayv ia afta dɛn dɔn no se dɛn gɛt di sik. Bɔt we wi de tink bɔt dɛn rit ya we pipul dɛn kin liv, i impɔtant fɔ mɛmba se dɛn tin ya na ɛstimat bay di ɛkspiriɛns we wan big grup pan pipul dɛn we gɛt CLL dɔn gɛt. Bɔrku tin kin afɛkt dɛn kayn we ya fɔ liv, lɛk yu jɛnɛral wɛl bɔdi, di stej wae yu sik de wae dɛn no bɔt yu sik, ɛn aw yu sik kin ansa fayn fayn wan to tritmɛnt. If yu gɛt kwɛstyɔn, aks yu dɔktɔ wetin fɔ ɛkspɛkt bay di tin we de apin to yu.

Wetin kin apin na di ɛnd-stej fɔ CLL?

Di wɔd "ɛnd-stej" min se di tritmɛnt dɛn nɔ de wok igen fɔ kɔntrol ɔ stɔp di CLL sik. Da tɛm de, yu kin gɛt infɛkshɔn we go mek yu day ɔ yu nɔ go ebul fɔ kɔntrol yu blɔd we dɔktɔ dɛn nɔ go ebul fɔ mɛn.

Yu tink se dɛn go ebul fɔ mek dis tin nɔ apin?

Naw, no we nɔ de we dɛn no fɔ mek dɛn nɔ gɛt CLL.

Aw i tan lɛk fɔ liv wit CLL?

I dipen pan di tin we de apin to yu. Yu kin gɛt CLL we nɔ gɛt ɛni sayn. If yu gɛt sɔm kayn sik, tritmɛnt dɛn de fɔ ridyus dɛn ɛn kɔntrol di sik. Bɔt, di sik nɔ go dɔn kpatakpata.

Na sɔm advays dɛn we go ɛp yu we yu de liv wit CLL:

• Protɛkt yusɛf frɔm infɛkshɔn:Pipul wae gɛt CLL kin gɛt bɔrku risk fɔ gɛt infɛkshɔn. Sɔm infɛkshɔn kin mek pɔsin in layf de pan denja. Aks yu dɔktɔ bɔt us vaysin dɛn we fayn fɔ yu.
• Pe atɛnshɔn to yu jenɛral wɛlbɔdi: Yu kin gɛt mɔ risk fɔ gɛt kansa na yu skin, kansa na yu lɔng, ɔ kansa na yu kɔlon. Aks yu dɔktɔ bɔt di tɛst fɔ no if pɔsin gɛt kansa.
• Manej strɛs: Bɔrku pipul dɛm wae gɛt CLL kin go tru saykl dɛm wae de mek dɛn nɔr gɛt dis sik ɛn dɛn kin kam bak. As di sik de go bifo, yu kin fil wɔri ɛn fred. If na so, aks yu dɔktɔ bɔt program ɔr savis dɛm wae go ɛp yu fɔ kɔntrol yu strɛs.
• It fayn it: Sɔm CLL simptom kin mek yu nɔr want fɔ it. Tɔk to yu dɔktɔ bɔt fɔ gɛt advays frɔm pɔsin we sabi bɔt it. If yu want fɔ it fayn, tray fɔ it tin dɛn we gɛt bɛtɛ tin fɔ it, we gɛt tin dɛn we nɔ gɛt bɔdi, ɔl gren, frut ɛn vɛjitebul, ɛn fayn fayn fat. Dis kin mek yu ɔl gɛt wɛlbɔdi.
• Ɛksesaiz: Ɛksesaiz de ɛp yu fɔ kɔntrol strɛs ɛn mek yu gladi.
• Rɛst: CLL kin mek yu fil taya bad bad wan. Rɛst we yu fil se yu nid fɔ rɛst.
• No wetin fɔ ɛkspɛkt: No na pawa. Aks yu dɔktɔ fɔ sayn dɛm wae de sho se yu sik kin de wɔs. If na so, yu dɔktɔ kin tɛl yu ɔda tritmɛnt dɛn we go ɛp fɔ mek yu ebul fɔ kɔntrol yu CLL fayn fayn wan.

Us kwɛstyɔn dɛn a fɔ aks mi dɔktɔ?

Yu kin aks kwɛstyɔn dɛn lɛk dɛn wan ya:

• Us kayn kronik lymphocytic leukemia a gɛt?
• A nɔ gɛt ɛni simptom. Ustɛm a fɔ bigin fɔ trit mi?
• Us tritmɛnt opshɔn dɛn a gɛt?
• A go gɛt fɔ tek tritmɛnt sote go?
• Yu tink se tritmɛnt go mek a nɔ gɛt prɔblɛm?

Fɔ dɔn, tin dɛn fɔ mɛmba (Take-Home Message) .

Krεse lymphocytic leukemia (CLL) na wan kayn lukimiya wae kin kam pan big pipul dεm. Yu kin gɛt dis sik fɔ lɔng tɛm ɛn nɔr gɛt ɛni sayn. If yu gɛt CLL, yu nɔ go nid fɔ bigin tritmɛnt wantɛm wantɛm. Pan ɔl we dɔktɔ dɛn nɔ kin ebul fɔ mɛn am kpatakpata, tritmɛnt dɛn de we kin mek pɔsin nɔ gɛt CLL ɛn mek di sik nɔ de igen . Sɔm pipul dɛm wae gɛt CLL de liv fɔ lɔng lɔng tɛm.

Fɔ liv wit wan sik wae nɔr de mɛn lɛk CLL nɔr kin izi ɔltɛm. Yu kin go tru sɔm saykl dɛm fɔ rɛmishɔn ɛn fɔ kam bak. Insay ɛni saykl, yu kin wɔri bɔt wetin go apin nɛks. Yu dɔktɔ dɛn ɔndastand aw i tan lɛk fɔ liv wit wan sik we nɔ de mɛn. Dɛn go gladi fɔ ansa ɛni kwɛstyɔn we yu gɛt ɛn ɛp yu ɛni we we dɛn ebul. So, nɔ ɛva fred fɔ tɔk to yu dɔktɔ bɔt di tin dɛn we de mɔna yu.

` Lukimiya, CLL, blɔd kansa, di simptom dɛm, tritmɛnt, limfosayt dɛm, fɔ wɛl